NSE:GLAXO's Forward Dividend Yield % is ranked better than 55.05% of 505
companies
in the Drug Manufacturers industry
Industry Median: 2.14
vs NSE:GLAXO: 2.42
During the past 12 months, GlaxoSmithKline Pharmaceuticals's average Dividends Per Share Growth Rate was 31.30% per year.
During the past 3 years, the average Dividends Per Share Growth Rate was 11.90% per year.
During the past 5 years, the average Dividends Per Share Growth Rate was 12.00% per year.
During the past 10 years, the average Dividends Per Share Growth Rate was 5.80% per year.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of GlaxoSmithKline Pharmaceuticals was 45.80% per year. The lowest was -17.60% per year. And the median was 11.60% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
GlaxoSmithKline Pharmaceuticals Forward Dividend Yield % Related Terms
NSE:GLAXO vs LLY, JNJ, ABBV: Forward Dividend Yield % Comparison
For the Drug Manufacturers - General subindustry, GlaxoSmithKline Pharmaceuticals's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GlaxoSmithKline Pharmaceuticals Forward Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pharmaceuticals's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where GlaxoSmithKline Pharmaceuticals's Forward Dividend Yield % falls into.
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
GlaxoSmithKline Pharmaceuticals Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
INR 57.000000
2026-05-29
2026-05-29
2026-07-01
Cash Dividend
annually
INR:INR 1.000000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Forward Dividend Yield % of 2.42% mean?
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) has a Forward Dividend Yield % of 2.42% as of Jun. 28, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on GlaxoSmithKline Pharmaceuticals and its competitors. According to the industry distribution chart, GlaxoSmithKline Pharmaceuticals ranks #227 out of 505 companies in the Drug Manufacturers industry, placing it in the top 45%.
Is GlaxoSmithKline Pharmaceuticals' Forward Dividend Yield % too high?
GlaxoSmithKline Pharmaceuticals' current Forward Dividend Yield % is 2.42%. The Drug Manufacturers industry median Forward Dividend Yield % is 2.14. GlaxoSmithKline Pharmaceuticals' value of 2.42% is 13.1% above this industry median. Based on the distribution chart, GlaxoSmithKline Pharmaceuticals ranks #227 out of 505 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, GlaxoSmithKline Pharmaceuticals has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pharmaceuticals' Forward Dividend Yield % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, GlaxoSmithKline Pharmaceuticals ranks #227 out of 505 companies for Forward Dividend Yield %. This puts GlaxoSmithKline Pharmaceuticals in the upper half of its industry. The industry median Forward Dividend Yield % is 2.14. GlaxoSmithKline Pharmaceuticals' value of 2.42% is 13.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Drug Manufacturers company?
The median Forward Dividend Yield % among Drug Manufacturers companies is 2.14, based on 505 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GlaxoSmithKline Pharmaceuticals's current Forward Dividend Yield % of 2.42% is 13.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on GlaxoSmithKline Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Forward Dividend Yield % is 2.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GlaxoSmithKline Pharmaceuticals's current Forward Dividend Yield % is 2.42%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹2,610.20, compared to a current price of ₹2,354.80 — trading 9.8% below its estimated fair value. The current Forward Dividend Yield % is 2.42% and 13.1% above the Drug Manufacturers industry median of 2.14. GlaxoSmithKline Pharmaceuticals' overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For GlaxoSmithKline Pharmaceuticals (NSE:GLAXO), the current Forward Dividend Yield % is 2.42% as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Overvalued in 2026?
Based on GuruFocus' analysis, GlaxoSmithKline Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹2,354.80 is trading 9.8% below its estimated GF Value™ of ₹2,610.20.
GuruFocus considers GlaxoSmithKline Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for NSE:GLAXO:
Forward Dividend Yield %: 2.42%
GF Value™: ₹2,610.20 vs. price of ₹2,354.80 (9.8% below fair value)
Industry Position: 13.1% above the Drug Manufacturers median (#227 of 505)
No single metric tells the full story. See the NSE:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GlaxoSmithKline Pharmaceuticals Business Description
GlaxoSmithKline Pharmaceuticals Ltd is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals. It is healthcare organisation focused on uniting science, technology and talent to get ahead of disease. The company's product portfolio comprises a broad range of General Medicines which includes anti-infectives, pain management, vitamins, minerals, nutritionals, hormones, dermatologicals, vaccines for both children and adults, and specialty medicines for respiratory and oncology. Its focused brands are Augmentin, Ceftum, Flutivate, T-bat, Betnovate, Neosporin, Tenovate, Physiogel, Calpol and Calpol T. The company has single reportable segment. The company has presence in India, and also Outside India. It generates majority of revenue from India.
73GF Score
Get the complete analysis for NSE:GLAXO
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GLAXO has been successfully added to your 